LC
SLNO

Lindbrook Capital’s Soleno Therapeutics SLNO Stock Holding History

Lindbrook Capital’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-627
Closed -$22K – 1872
2020
Q1 		$22K Sell
627
-106
-14% -$4.51K 0.01% 516
2019
Q4 		$32K Buy
+733
New +$18.8K 0.01% 579
2019
Q3 		– Sell
-733
Closed -$30K – 1528
2019
Q2 		$30K Buy
+733
New +$25.3K 0.01% 576

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lindbrook Capital's SLNO Position: Q2 2020 in Review

Lindbrook Capital sold out of Soleno Therapeutics (SLNO) in Q2 2020, closing a stake of 627 shares — an estimated $22K sold.

Lindbrook Capital first reported a position in SLNO in Q2 2019 and held it in 3 quarters. The position peaked at $32K in Q4 2019. 64 funds tracked by Wall St. Rank hold SLNO as of Q2 2020.

  • Lindbrook Capital reported no remaining Soleno Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Lindbrook Capital sold 627 Soleno Therapeutics shares in Q2 2020, an estimated $22K.
  • Lindbrook Capital first reported a position in Soleno Therapeutics in Q2 2019 and held it in 3 quarters.
  • Lindbrook Capital's Soleno Therapeutics position peaked at $32K in Q4 2019.
  • 64 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2020.

Based on Lindbrook Capital's 13F filing for Q2 2020, filed 27 Jul 2020.